Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy

Front Immunol. 2021 Aug 12:12:721738. doi: 10.3389/fimmu.2021.721738. eCollection 2021.

Abstract

Here, we described the case of a B cell-deficient patient after CD19 CAR-T cell therapy for refractory B cell Non-Hodgkin Lymphoma with protracted coronavirus disease 2019 (COVID-19). For weeks, this patient only inefficiently contained the virus while convalescent plasma transfusion correlated with virus clearance. Interestingly, following convalescent plasma therapy natural killer cells matured and virus-specific T cells expanded, presumably allowing virus clearance and recovery from the disease. Our findings, thus, suggest that convalescent plasma therapy can activate cellular immune responses to clear SARS-CoV-2 infections. If confirmed in larger clinical studies, these data could be of general importance for the treatment of COVID-19 patients.

Keywords: CD19 CAR-T cell; COVID – 19; NK cell; SARS – CoV – 2; T cell; convalescent plasma (CP).

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • B-Lymphocytes* / immunology
  • COVID-19 / complications
  • COVID-19 / immunology*
  • COVID-19 / therapy*
  • COVID-19 Serotherapy
  • Female
  • Humans
  • Immunization, Passive
  • Immunoglobulins, Intravenous
  • Immunologic Deficiency Syndromes / complications
  • Immunologic Deficiency Syndromes / immunology*
  • Immunotherapy, Adoptive*
  • Killer Cells, Natural / immunology*
  • Lymphocyte Activation
  • Lymphopoiesis
  • SARS-CoV-2
  • T-Lymphocytes / immunology*
  • Viral Load

Substances

  • Immunoglobulins, Intravenous